Celltrion received approval of Phase 3 clinical trial pla of 'CT-P10'
On June 29, Ministry of Food and Drug Safety approved Phase 3 clinical trial pla of 'CT-P10' from Celltrion. 'CT-P10' is a biosimilar product of MabThera (ingredient name: rituximab) which is for the treatment of rheumatoid arthritis and non-Hodgkin's lymphoma.
The Phase 3 clinical trial will be...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
